AVIR ATEA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ATEA PHARMACEUTICALS INC reported revenue of n/a, net income of −$32.9M and diluted EPS of −$0.41; for the fiscal year ended December 2025 revenue was n/a.
AVIR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$181M, net income −$158M (margin n/a), EPS −$1.94
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$193M, net income −$168M (margin n/a), EPS −$2.00
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$164M, net income −$136M (margin n/a), EPS −$1.63
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$131M, net income −$116M (margin n/a), EPS −$1.39
- Fiscal year ended Dec 2021: revenue $351M, gross profit n/a, operating income $138M, net income $121M (margin 34.4%), EPS $1.37
AVIR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$32.9M, EPS −$0.41
- Quarter ended Mar 31, 2026: revenue n/a, net income −$45.4M, EPS −$0.57
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$44.5M, EPS −$0.57
- Quarter ended Sep 30, 2025: revenue n/a, net income −$42.0M, EPS −$0.53
- Quarter ended Jun 30, 2025: revenue n/a, net income −$37.2M, EPS −$0.44
- Quarter ended Mar 31, 2025: revenue n/a, net income −$34.3M, EPS −$0.40
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$33.2M, EPS −$0.40
- Quarter ended Sep 30, 2024: revenue n/a, net income −$31.2M, EPS −$0.37
- Quarter ended Jun 30, 2024: revenue n/a, net income −$40.5M, EPS −$0.48
- Quarter ended Mar 31, 2024: revenue n/a, net income −$63.2M, EPS −$0.75
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$39.2M, EPS −$0.46
- Quarter ended Sep 30, 2023: revenue n/a, net income −$33.1M, EPS −$0.40
- Quarter ended Jun 30, 2023: revenue n/a, net income −$28.2M, EPS −$0.34
- Quarter ended Mar 31, 2023: revenue n/a, net income −$35.5M, EPS −$0.43
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$34.5M, EPS −$0.40
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.07M, EPS −$0.10
- Quarter ended Jun 30, 2022: revenue n/a, net income −$31.3M, EPS −$0.38
- Quarter ended Mar 31, 2022: revenue n/a, net income −$42.1M, EPS −$0.51
- Quarter ended Dec 31, 2021 (from the annual report): revenue $192M, net income $117M, EPS $1.35
- Quarter ended Sep 30, 2021: revenue $32.8M, net income −$28.2M, EPS −$0.34
AVIR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$132M, share buybacks $25.5M
- Fiscal year ended Dec 2024: operating cash flow −$135M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow −$85.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$121M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$87.0M, share buybacks n/a
AVIR balance sheet
- Jun 30, 2026: cash $76.5M, total assets $232M, total liabilities n/a, shareholders' equity $204M
- Mar 31, 2026: cash $79.3M, total assets $267M, total liabilities n/a, shareholders' equity $234M
- Dec 31, 2025: cash $95.7M, total assets $315M, total liabilities $39.8M, shareholders' equity $275M
- Sep 30, 2025: cash $77.3M, total assets $343M, total liabilities $27.2M, shareholders' equity $316M
- Jun 30, 2025: cash $87.7M, total assets $392M, total liabilities $27.2M, shareholders' equity $364M
- Mar 31, 2025: cash $119M, total assets $440M, total liabilities $28.9M, shareholders' equity $411M
- Dec 31, 2024: cash $64.7M, total assets $465M, total liabilities $25.8M, shareholders' equity $439M
- Sep 30, 2024: cash $98.5M, total assets $491M, total liabilities $32.4M, shareholders' equity $459M
Is AVIR profitable?
No. ATEA PHARMACEUTICALS INC lost $165M over the last four quarters.
What is AVIR's EPS?
Diluted earnings per share over the last four quarters were −$2.08; −$0.41 in the latest quarter.